TEAM

CURRENT MEMBERS

Postdoctoral researchers

Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury

To be completed in 2021

Promoter: Mathieu Vinken

Dr. Pharm. Vânia Vilas-Boas

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Doctoral researchers

The role of connexins, pannexins and their channels in cholestasis

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Alanah Pieters

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be completed in 2022

Promoter: Mathieu Vinken

Dr. Pharm. Bruna dos Santos Rodrigues

Development and testing of new inhibitors of Cx43 hemichannels and Panx1 channels

To be completed in 2024

Promoter: Mathieu Vinken

Dr. M. Sci. Andrés Tabernilla

Pharm. Axelle Cooreman

The role of connexins, pannexins and their channels in cholestasis

To be defended in 2022

Promoters: Mathieu Vinken, Pieter Annaert

Pharm. Eva Gijbels

Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury

To be defended in 2022

Promoters: Mathieu Vinken, Lindsey Devisscher

Co-promoter: Tamara Vanhaecke

M. Sci Emma Gustafson

Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study

To be defended in 2022

Promoters: Mathieu Vinken, Tamara Vanhaecke

M. Sci Kaat Leroy

The role of connexins, pannexins and their channels in liver cancer

To be defended in 2022

Promoter: Mathieu Vinken

Co-promoter: Bruno Cogliati

Pharm. Raf Van Campenhout

Development of nanobody-based inhibitors of connexin hemichannels and pannexin channels as novel therapeutics for the treatment of liver disease

To be defended in 2022

Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans

M. Pharm. Sci. Anne Caufriez

Development and in vitro testing of peptidomimetic-based inhibitors of pannexin1 channels

To be defended in 2023

Promoters: Mathieu Vinken, Steven Ballet

 

 

 

 

 

 

 

 

 

 

 

 

Scientific collaborators

The role of connexin43 hemichannels and pannexin1 channels in liver cancer

To be defended in 2024 (University of São Paulo-Brazil)

Promoters: Bruno Cogliati, Mathieu Vinken

M. Sci. Cícero Júlio Silva Costa

Development of nanobody-based inhibitors of connexin43 hemichannels

To be completed in 2021

Promoter: Mathieu Vinken

M. Sci. Ana Rita Coelho Gomes

 

 

Technicians

Dinja De Win

Tâmara Prandini

   Manon Wery

FORMER TEAM MEMBERS

Dr. M. Sci. Sara Crespo-Yanguas

Dr. Pharm. Michaël Maes

Dr. Pharm. Joost Willebrords

Miss Tineke Vanhalewyn

FINISHED POSTDOCTORAL PROJECTS

Role of connexin and pannexin (hemi)channels in liver cancer

Tereza Cristina da Silva: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

Role of connexin and pannexin (hemi)channels in hepatitis

Isabel Veloso Alves Pereira: completed 31/03/2017

Promoters: Mathieu Vinken, Bruno Cogliati

 

 

FINISHED DOCTORAL PROJECTS

Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures

Tatyana Doktorova: defended 16/03/2012

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes

Eva Ramboer: defended 15/10/2015

Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers

 

The role of connexins, pannexins and their channels in acute liver failure

Michaël Maes: defended 17/10/2017

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis

Joost Willebrords: defended 29/01/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

The role of connexins, pannexins and their channels in liver fibrosis

Sara Crespo Yanguas: defended 25/10/2018

Promoters: Mathieu Vinken, Bruno Cogliati

 

Connexin43 hemichannels as druggable targets for future anti-seizure medication

Laura Walrave: defended 24/01/2019

Promoter: Ilse Smolders

Co-promoters: Mathieu Vinken, Luc Leybaert

© 2023 by InVitroTox Consulting.

Proudly created using Wix.com

  • LinkedIn Social Icon